(Q43566892)

24 November 2017

The significance of dihydropyrimidine dehydrogenase (DPD) activity in bladder cancer (English)

1 reference

24 November 2017

Mizutani Y

1

1 reference

24 November 2017

Wada H

2

1 reference

24 November 2017

Fukushima M

3

1 reference

24 November 2017

Yoshida O

4

1 reference

24 November 2017

Ukimura O

5

1 reference

24 November 2017

Kawauchi A

6

1 reference

24 November 2017

Miki T

7

1 reference

24 November 2017

1 March 2001

1 reference

European Journal of Cancer

24 November 2017

1 reference

24 November 2017

37

1 reference

24 November 2017

569-575

1 reference

24 November 2017

5

1 reference

Prophylactic oral UFT therapy for superficial bladder cancer

24 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900440-8

7 January 2021

Early intravesical instillation of adriamycin with oral administration of 5-fluorouracil after transurethral resection for superficial bladder cancer: preliminary results

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900440-8

7 January 2021

Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900440-8

7 January 2021

Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900440-8

7 January 2021

Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900440-8

7 January 2021

Doxorubicin sensitizes human bladder carcinoma cells to Fas-mediated cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900440-8

7 January 2021

Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900440-8

7 January 2021

Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900440-8

7 January 2021

Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900440-8

7 January 2021

Overcoming tumor necrosis factor-alpha resistance of human renal and ovarian carcinoma cells by combination treatment with buthionine sulfoximine and tumor necrosis factor-alpha. Role of tumor necrosis factor-alpha mRNA down-regulation in tumor cell

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900440-8

7 January 2021

Effect of glutathione and its related enzymes on chemosensitivity of renal cell carcinoma and bladder carcinoma cell lines.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900440-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900440-8

1 reference

7 January 2021

Metallothionein expression is correlated with cisplatin resistance in transitional cell carcinoma of the urinary tract

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900440-8

7 January 2021

Decreased catabolism of fluorouracil in peripheral blood mononuclear cells during combination therapy with fluorouracil, leucovorin, and interferon alpha-2a

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900440-8

7 January 2021

Relationship between protein levels and gene expression of dihydropyrimidine dehydrogenase in human tumor cells during growth in culture and in nude mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900440-8

7 January 2021

10.1016/S0959-8049(00)00440-8

Identifiers

DOI

1 reference

24 November 2017

1 reference